The drug eluting balloon (DEB) market has emerged as an effective treatment option for coronary artery disease. DEBs are angioplasty balloons coated with an antiproliferative drug to prevent re-narrowing of coronary arteries. The balloons are used in percutaneous coronary intervention (PCI) to deliver the drug to the treatment site during angioplasty procedures. DEBs offer advantages over drug eluting stents such as lower risks of stent fracture and thrombosis. The growing prevalence of cardiovascular diseases and rising number of PCI procedures globally are major factors driving the demand for DEBs. The global Drug Eluting Balloon Market is estimated to be valued at US$ 769.29 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing burden of cardiovascular diseases, especially coronary artery disease, propels the growth of the DEB market. As per the World Health Organization (WHO), cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Moreover, developed regions such as North America and Europe have significant elderly populations prone to atherosclerosis and heart diseases. Increasing risk factors such as smoking, physical inactivity and unhealthy diets are further contributing to the rising incidence of CVDs globally. This is expected to augment the demand for PCI procedures using drug eluting balloons during the forecast period.
SWOT Analysis
Strength: Drug eluting balloons offer location-specific drug delivery for the treatment of coronary artery disease and peripheral artery disease without systemic drug exposure. The risk of re-stenosis is also significantly reduced compared to angioplasty alone.
Weakness: High costs associated with drug eluting balloons limit their widespread adoption. The long-term efficacy and safety profile is also not clearly established compared to drug-eluting stents.
Opportunity: Increasing prevalence of cardiovascular diseases worldwide presents an opportunity for drug eluting balloon manufacturers. Ongoing research to expand indications such as de-novo lesions also offers scope for market growth.
Threats: Stricter regulatory approvals and frequent product recalls pose significant challenges. Established drug-eluting stent brands further intensify market competition.
Key Takeaways
The global Drug Eluting Balloon Market Share is expected to witness high growth. The market size was valued at US$ 769.29 billion in 2024 and is anticipated to reach US$ 1454.09 billion by 2031, expanding at a CAGR of 8.6% during the forecast period.
Regional analysis: North America was the largest regional market for drug eluting balloons in 2024. The rising burden of cardiovascular diseases, growing geriatric population, and strong reimbursement policies are major factors driving market growth. Europe is also a significant regional market supported by increasing research & development activities for advanced DEB technologies in countries like Germany, Italy and France.
Key players operating in the drug eluting balloon market are Oracle Corporation (NetSuite Inc.), BatchMaster Software, Columbus Manufacturing, Aquilon Software, CompuTec S.A.(ProcessForce), Datacor Chempax, DESKERA, ERPAG, Fishbowl, Intellect, SAGE GROUP plc, and VAI - Vormittag Associates, Inc. Major players are focusing on new product approvals and geographical expansion to strengthen their market position.
For more insights, read- https://www.newswirestats.com/drug-eluting-balloon-market-size-and-outlook-2023-2030/
For more details on the report, Read- https://dailynewsmotion.weebly.com/report-blog/under-the-hood-a-comprehensive-guide-to-the-automotive-parts-remanufacturing-market
Drug eluting balloon catheter is witnessing robust adoption owing to its overwhelming results in cardiovascular and peripheral artery procedures.
Moreover, drug eluting balloon catheter is also turning out to be useful for patients who are unable to undergo percutaneous coronary intervention (PCI) procedures.
Encouraged by this situation, various drug eluting balloon catheter manufacturers across the globe are now increasing their production capacity.
The aforementioned factors are reflecting favourably on the global sales of the drug eluting balloon catheter.Also, companies are aiming to manufacture cost-effective catheters that in order to increase market penetration.
Growing prevalence of cardiovascular diseases and soaring incidences of cardiology intervention procedures is facilitating the growth of the global drug eluting balloon catheter market.
Fact.MR projects that the global market for drug eluting balloon catheter will surge at a robust CAGR between 2018 and 2022.In addition, factors such as enhanced reimbursement policies, rising geriatric population and growing healthcare expenditure are anticipated to positively impact the market’s growth.
